| |
| According to THE SAGE GROUP, Technological Innovation is the Key to the Future of Stenting in the Lower Limbs ATLANTA, September 12, 2007 (BUSINESS WIRE)—THE SAGE GROUP recently published three new reports analyzing the Peripheral Arterial Disease (PAD) interventional market based on specific devices or therapies. PAD procedures include revascularization with surgery or endovascular devices, as well as amputation. According to Mary L. Yost, President, “PAD revascularization procedures represent a sizeable and rapidly growing market opportunity for endovascular devices. Market expansion reflects an increasing number of patients diagnosed and treated, as well as new technologies replacing other therapies.” “By 2020 the endovascular market is projected to exceed 2.5 million procedures. Technological innovation is the key factor that will determine whether the 1.9 million additional endovascular procedures are treated with angioplasty/atherectomy devices or primary stenting,” stated Yost. “Primary stenting, or stent deployment without prior dilation with angioplasty, is an alternative to revascularization with angioplasty or atherectomy devices,” she explained. “While primary stenting represents the majority in the aortoiliac region, it is relatively uncommon in the femoropopliteal vessels, and almost nonexistent in the below knee area. We expect that primary stenting will remain the preferred procedure in the aortoiliac and continue to gain share over time,” Ms. Yost predicted. “The stent market opportunity in the lower limbs also includes provisional stents, or those implanted following angioplasty or atherectomy. Approximately 260,000 primary and provisional stents were deployed in 2005,” elaborated Yost. “Although many promising new stent technologies are being investigated in the lower limbs, we believe that at the present time there is insufficient data to determine which, if any, of the new stents might prove successful in the difficult SFA (superficial femoral artery) and tibial territories,” declared Ms. Yost. “Reflecting concerns about stent fracture and migration, in 2005 lower limb stent procedures declined for the first time in 8 years. We expect that interventionalists will continue to be cautious regarding SFA stent deployment until either new stent technologies become available or more data is published on stents currently marketed,” Yost observed. “The key question is what happens to stent procedures in the femoropopliteal and tibioperoneal regions,” Ms. Yost declared. “In order to address this question so that we could forecast stent procedures, we developed two sophisticated endovascular models based on a series of complex assumptions regarding the future of primary and provisional stenting,” she elaborated. About Peripheral Arterial Disease PAD, also known as Peripheral Vascular Disease (PVD) or Peripheral Arterial Occlusive Disease (PAOD), is characterized by a reduction of blood flow to the lower limbs due to atherosclerosis, commonly called hardening of the arteries. Atherosclerosis is a disease in which the walls of the arteries thicken and harden as a result of the build-up of fatty deposits (plaque) on their inner lining. Peripheral Arterial Disease Interventional Market Analysis Based on Primary and Provisional Stenting. Employing ICD-9 data, this report analyzes the current PAD interventional market based on treatment with primary and provisional stenting. THE SAGE GROUP’S PAD Projections Model is employed to forecast endovascular and surgical procedures through 2020. Angioplasty/atherectomy, primary stent, provisional stent and total endovascular procedures are analyzed by vascular territory in the aortoiliac, femoropopliteal, and tibioperoneal regions and projected through 2020. Femoropopliteal and tibioperoneal forecasts for angioplasty/atherectomy and stenting are based on two assumptions regarding the future role of infrainguinal primary stenting. The optimistic case assumes primary stents gain share, while the pessimistic case assumes that primary stents decline. For additional information http://www.thesagegroup.us/IntervMktStents/IntervMktStentreprt.html The other two reports in this series are: Peripheral Arterial Disease Interventional Market Analysis Based on Potential Treatment with Perioperative Oral Antiplatelet Therapy and Peripheral Arterial Disease Interventional Market Analysis Based on Treatment with Angioplasty or Atherectomy. THE SAGE GROUP, a research and consulting company, specializes in vascular disease in the lower limbs. For additional information visit www.thesagegroup.us. SOURCE: THE SAGE GROUP THE SAGE GROUP, Atlanta |